This topic contains a solution. Click here to go to the answer

Author Question: Purchasing power parity may not hold in practice due to all of the following except A) ... (Read 65 times)

Pineappleeh

  • Hero Member
  • *****
  • Posts: 585
Purchasing power parity may not hold in practice due to all of the following except
 
  A) transportation costs.
  B) cross-country differences in environmental regulations.
  C) trade barriers like tariffs and quotas.
  D) the existence of non-traded goods.

Question 2

Prices are regarded as sticky in ________.
 
  A) new Keynesian and traditional Keynesian theory
  B) real business cycle and new Keynesian theory
  C) real business cycle and traditional Keynesian theory
  D) traditional Keynesian, new Keynesian and real business cycle theory



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

Liamb2179

  • Sr. Member
  • ****
  • Posts: 365
Answer to Question 1

B

Answer to Question 2

A




Pineappleeh

  • Member
  • Posts: 585
Reply 2 on: Jun 30, 2018
Gracias!


peter

  • Member
  • Posts: 330
Reply 3 on: Yesterday
YES! Correct, THANKS for helping me on my review

 

Did you know?

When Gabriel Fahrenheit invented the first mercury thermometer, he called "zero degrees" the lowest temperature he was able to attain with a mixture of ice and salt. For the upper point of his scale, he used 96°, which he measured as normal human body temperature (we know it to be 98.6° today because of more accurate thermometers).

Did you know?

Drug-induced pharmacodynamic effects manifested in older adults include drug-induced renal toxicity, which can be a major factor when these adults are experiencing other kidney problems.

Did you know?

Medication errors are more common among seriously ill patients than with those with minor conditions.

Did you know?

Aspirin is the most widely used drug in the world. It has even been recognized as such by the Guinness Book of World Records.

Did you know?

As of mid-2016, 18.2 million people were receiving advanced retroviral therapy (ART) worldwide. This represents between 43–50% of the 34–39.8 million people living with HIV.

For a complete list of videos, visit our video library